This curriculum is designed to address the operational, clinical, and logistical challenges of integrating bispecific antibody (bsAb) therapies across the RWJBarnabas Health system. Building on established academic protocols, the program guides community clinicians in adapting workflows for safe bsAb administration, clarifying team roles, and strengthening coordination with academic hubs. Through evidence-based modules and practical implementation strategies, participants from each RWJBarnabas Health site will enhance their ability to select and sequence bsAbs appropriately, manage toxicities, and ensure continuity of care and equitable access for patients with multiple myeloma and non-Hodgkin lymphoma.

CME/CE Accreditation Information